A Study of Irinotecan Liposome in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer Clinical Trial

Official title:

A Phase I Study to Evaluate the Safety and Tolerability of Irinotecan Liposome in Combination With Oxaliplatin and 5-FU/LV in the Treatment of Advanced Pancreatic Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04796948
• Other study ID #: HR-YLTKL-101
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: April 8, 2021
• Est. completion date: November 28, 2023

Study information

• Verified date: August 2023
• Source: Jiangsu HengRui Medicine Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine the safety and tolerability of irinotecan liposome in combination with oxaliplatin and 5-FU/LV in subjects with advanced pancreatic cancer who have not received prior systemic chemotherapy

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 41
• Est. completion date: November 28, 2023
• Est. primary completion date: November 28, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Males and females aged 18 to 70 years (including 18 and 70 years);

2. Patients with histologically or cytologically diagnosed pancreatic cancer (from pancreatic ductal epithelium), and clinical records show unresectable locally advanced or metastatic pancreatic cancer (stage III/IV based on the 8th Edition of the AJCC TNM staging for pancreatic cancer).

3. Have not received systemic anti-tumor therapy for the current stage of disease, including surgery (except stent placement), radiotherapy, chemotherapy, targeted therapy, immunotherapy or investigational therapy;

4. If the subject has previously received adjuvant chemotherapy, it is necessary to ensure that the time interval between the last dose and the first dose of this study is more than 12 months, and the adjuvant therapy-toxicity has recovered (judged as = grade 1 based on CTCAE 5.0 criteria);

5. Must have at least one measurable lesion that can be taken as the target lesion (according to the RECIST v1.1 criteria);

6. Eastern Cooperative Oncology Group (ECOG) performance status score: 0 - 1 point;

7. Expected survival =3 months;

8. Major organs are functioning well

Exclusion Criteria:

1. Patients with pancreatic cancer originating from extrapancreatic ductal epithelium, including pancreatic neuroendocrine carcinoma, acinar cell carcinoma of the pancreas, pancreatoblastoma, and solid-pseudopapillary tumor;

2. Patients with known central nervous system metastases;

3. Patients carrying homozygous mutations of UGT1A1*28/*6 gene;

4. Severe gastrointestinal dysfunction;

5. Severe infection (> CTCAE grade 2), such as severe pneumonia, bacteremia, infection complications, etc. requiring inpatient treatment, occurred within four weeks before enrollment, and symptoms and signs of infection requiring intravenous antibiotic therapy (except for prophylactic antibiotics) occurred within two weeks before enrollment;

6. Received any of the following treatments:

1)Previously received treatment with irinotecan-containing regimens; 2)Received concomitant medications containing strong inhibitors/strong inducers of CYP3A4 or strong inhibitors of UGT1A1 within two weeks before enrollment; 3)Received the last anti-cancer treatment (including surgery, radiotherapy, etc.) within four weeks before enrollment; 4)Have received treatment with any other investigational drug/device within four weeks before enrollment; 5)Enrolled in another clinical study at the same time unless it is an observational (non-interventional) clinical study or an interventional clinical study follow-up. 7.Having experienced an arteriovenous thrombotic event, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism, within one year before enrollment; 8.Patients with cardiac clinical symptoms or diseases that are not well controlled, such as: (1) Patients with NYHA class 2 and above cardiac failure; (2) unstable angina; (3) myocardial infarction that occurred within one year; (4) clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention. 9.Patients who have suffered from malignant tumors other than pancreatic cancer before using the study drug for the first time, except those with low risk of metastasis and death (5-year survival rate >90%), such as adequately treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin; 10.Have any contraindication to either irinotecan liposome, irinotecan, 5-FU, calcium folinate, or oxaliplatin;

Related Conditions & MeSH terms

• Advanced Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• Irinotecan liposome;oxaliplatin;5-FU(Fluorouracil Injection);LV(Calcium Folinate Injection)
irinotecan liposome in combination with oxaliplatin and 5-FU/LV

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MTD	Maximum tolerated dose for patients in combination treatment.	18 months
Primary	RP2D	Recommended phase II dose for patients in combination treatment.	18 months
Secondary	Frequency and severity of AEs/SAEs as Assessed by CTCAE v5.0	Through laboratory test, physical examination, vital signs,12-lead electrocardiogram (ECG), Echocardiogram, etc.;	From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.
Secondary	Objective Response Rate (ORR)	Number of reported responses (complete [CR] and partial [PR]) divided by the number of reported assessable patients.	From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.
Secondary	Disease Control Rate (DCR)	Based on investigator reviewed radiographic tumour assessment and death.	From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months
Secondary	Duration of Response (DoR)	Based on investigator reviewed radiographic tumour assessment and death.	From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.
Secondary	Progression-Free Survival (PFS)	Based on change in tumour per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1	From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.
Secondary	Overall Survival (OS)	Based on investigator reviewed radiographic tumor assessment and death.	From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.
Secondary	Cmax	peak plasma concentration	28days
Secondary	Tmax	time to peak concentration	28days
Secondary	AUC	area under the plasma concentration versus time curve	28days
Secondary	t1/2z	elimination half-life	28days
Secondary	Vss	steady-state apparent volume of distribution	28days
Secondary	CL	clearance	28days